A Double-blind, Randomised, Placebo-controlled, Multi-center Study to Evaluate Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs Estetrol (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Pantarhei Oncology
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2018 Status changed from not yet recruiting to recruiting.
- 29 Mar 2018 Planned End Date changed from 30 Apr 2019 to 30 May 2019.